However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

Biocon Biologics and Civica, Inc. on Thursday announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. According to the company’s ...

Biocon Biologics and Civica announce agreement to expand access and affordability of Insulin Aspart in the U.S. Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug ...

Under the terms of the agreement, Biocon Biologics will supply insulin aspart drug substance to Civica, who will use the drug substance to produce insulin aspart drug product, a rapid-acting insulin ...

Novo Nordisk provided the insulin aspart that was used in the trial. Continuous glucose monitor sensors and transmitters were purchased from Dexcom at a discounted price.

"Discover Civica Rx's plans for 2025, including launching new medications from their plant, expanding insulin program, and ...

Pharmac is seeking public feedback on a proposal to fund a new, additional type of insulin for people with diabetes from 1 May 2025. The new medicine (branded as Ryzodeg) is a combination of two other ...

an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart. Sanofi-Aventis' Merilog version of the product has been cleared for the treatment of adult and ...

Biocon shares traded 1% higher at Rs 337.15 in early trade on Friday, following the company's announcement of its collaboration with Civica, a not-for-profit generic drug and pharmaceutical ...